USA Financial Formulas acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 16,664 shares of the biopharmaceutical company's stock, valued at approximately $1,539,000. Gilead Sciences accounts for about 0.2% of USA Financial Formulas' portfolio, making the stock its 16th largest position.
Other institutional investors have also recently bought and sold shares of the company. Avior Wealth Management LLC lifted its position in shares of Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after purchasing an additional 108 shares in the last quarter. Concord Asset Management LLC VA grew its stake in shares of Gilead Sciences by 3.8% during the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock valued at $256,000 after acquiring an additional 111 shares in the last quarter. TFB Advisors LLC increased its position in shares of Gilead Sciences by 1.2% during the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after acquiring an additional 116 shares during the last quarter. Sumitomo Life Insurance Co. grew its stake in Gilead Sciences by 0.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company's stock valued at $1,494,000 after purchasing an additional 117 shares in the last quarter. Finally, FDx Advisors Inc. grew its position in shares of Gilead Sciences by 2.2% during the third quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company's stock worth $450,000 after buying an additional 117 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Trading Up 1.5 %
Shares of NASDAQ GILD opened at $92.38 on Thursday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The business has a 50-day moving average price of $91.96 and a two-hundred day moving average price of $83.69. The firm has a market capitalization of $115.13 billion, a PE ratio of 1,026.44, a PEG ratio of 1.27 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The business's revenue for the quarter was up 7.0% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.
Insider Activity
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 8,500 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the completion of the sale, the chief financial officer now owns 132,373 shares in the company, valued at approximately $12,173,021.08. This trade represents a 6.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the firm's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 453,734 shares of company stock valued at $41,902,086 over the last 90 days. 0.29% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on GILD. Maxim Group lowered Gilead Sciences from a "buy" rating to a "hold" rating in a report on Friday, November 8th. Wells Fargo & Company upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Robert W. Baird boosted their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Finally, Oppenheimer raised their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $97.96.
View Our Latest Stock Analysis on Gilead Sciences
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
